Asset Planning,Inc Lineage Cell Therapeutics, Inc. Transaction History
Asset Planning,Inc
- $131 Billion
- Q4 2024
A detailed history of Asset Planning,Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Asset Planning,Inc holds 2,036 shares of LCTX stock, worth $1,221. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,036Holding current value
$1,221% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
122Shares Held
95.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$25 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.74 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$5.16 Million0.0% of portfolio
-
Defender Capital, Llc.5.96MShares$3.58 Million1.17% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$3 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $102M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...